8201 East Riverside Drive
Austin, TX 78744
XBiotech, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing ‘True Human’ monoclonal antibodies for treating various different diseases. Its lead product is Xilonix, a novel anti-cancer agent, which has completed enrollment of its pivotal, randomized double-blinded placebo controlled Phase III study in Europe for the treatment of advanced colorectal cancer. Xilonix targets and neutralizes interleukin-1 alpha (IL-1a), a molecule known to promote angiogenesis, growth, and spread of tumors, as well as mediate symptoms, such as metabolic dysregulation, fatigue, and anxiety associated with advanced cancer. The company also develops a proprietary True Human monoclonal antibody discovery platform and manufacturing system. XBiotech, Inc. was founded in 2005 and is headquartered in Austin, Texas.